Prospective randomized study of IVF-ET with GnRHa long protocol or Dienogest treatment before GnRHa long protocol in patients with endometriosis
- Conditions
- infertile women, endometriosis
- Registration Number
- JPRN-UMIN000005234
- Lead Sponsor
- Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine
- Brief Summary
The numbers of growing follicles, retrieved oocytes, fertilized oocytes, and blastocysts were significantly lower in the DNG group than in the control group. The fertilization and blastocyst rates were also lower in the DNG group than in the control group. Although there was no significant difference in the implantation rate between the groups, the cumulative pregnancy rate and live birth rate were lower in the DNG group than in the control group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 68
Not provided
1) patients who had GnRHa ultra long protocol last 6th month 2) patients who had DNG and/or EP treatment or GnRHa treatment ( > 3 month)for endometriosis 3) patients who has undiagnostic genital bleeding 4) a pregnant woman 5) patients who has estrogen dependence tumor (breast cancer, endometrial cancer) 6) patients who has history of breast cancer 7) patients who has Thrombophlebitis and/or Pulmonary thrombosis, or history of these disease. 8) patients who has the thromboembolism disease of the artery (coronary heart disease, Cerebral apoplexy) or history of these disease 9) patients who has liver dysfunction, or liver disease 10) patients who has Hypersensitivity to DNG, GnRHa, EP, FSH, HMG, HCG 11) patients who is judged to be inappropriate for this study by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pregnancy rate
- Secondary Outcome Measures
Name Time Method 1) total amount of FSH/HMG 2) number of growing follicle (<15mm) and mature follicle (<18mm), number of oocyte retrieved 3) fertilization rate, implantation rate 4) serum concentration of estradiol and progesterone (on the day hCG injection) 5) intrafollicular concentration of cytokines (interleukin-6, tumor necrosis factor alpha), oxidative stress markers (8-htdroxy-2'-deoxyguanosine, hexanoyl-lysine), Cu,Zn-superoxide dismutase 6) serum concentration of CA125 7) concentration of interleukin-6 and tumor necrosis factor alpha in peritoneal fluids